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It has long been recognized that familial breast cancer is associ-
ated with increased bilateral occurrence of this disease (Anderson,
1971). The identification of the BRCA1 and BRCA2 genes has
made it possible to more accurately determine hereditary breast
cancer risk for women who carry a germline mutation in one of
these genes. In BRCA1 mutation carriers there is a strongly
elevated life-time risk of breast cancer while the risk of contralat-
eral breast cancer has been estimated to be as high as 64% (Ford et
al, 1994). We previously reported that the rate of metachronous
contralateral disease in a group of BRCA1-associated breast
cancer patients (n = 49) was 19% after 5 years of follow-up, while
synchronous presentation occurred in 4% of the patients (Verhoog
et al, 1998). More recently, Robson and colleagues found that in a
group of 30 BRCA1/2 mutation carriers (diagnosed with breast
cancer before the age of 42) 31% developed contralateral breast
cancer within 5 years (Robson et al, 1998).
Because of the high risk of a second primary breast cancer,
affected BRCA1 mutation carriers and their physicians may have
to face the decision about more radical surgery, including
contralateral prophylactic mastectomy at the time of, or in the
years following, diagnosis of the first tumour. Therefore, it is of
interest to identify any subgroup of patients with hereditary breast
cancer which is particularly at risk of developing contralateral
breast cancer. With respect to the general population, the risk of
contralateral disease is clearly correlated with a younger age at
onset of the disease (Prior and Waterhouse, 1978; Hislop et al,
1984; Adami et al, 1985; Broët et al, 1995). This, however, could
primarily result from the fact that a larger proportion of breast
cancer occurring at a younger age is attributable to genetic suscep-
tibility. We investigated the risk of developing contralateral breast
cancer in relationship to age at diagnosis of the first breast cancer,
in women from families with an identified BRCA1 mutation.
PATIENTS AND METHODS
Families were identified through the Family Cancer Clinic of the
Daniel den Hoed Cancer Centre and the Department of Clinical
Genetics of the Erasmus University Rotterdam. The 83 families
that were eligible for this study consisted of consecutive unse-
lected families with an identified germline mutation in the BRCA1
gene. In total 24 different BRCA1 mutations were identified. The
presence of a BRCA1 mutation was detected by protein truncation
test, by allele-specific oligonucleotide hybridization for distinct
mutations or by PCR-analysis specific for two large genomic dele-
tions (Hogervorst et al, 1995; Petrij-Bosch et al, 1997). Whenever
possible, histological and clinical data from breast cancer patients
were collected through hospital records and pathology reports.
Follow-up data of 179 women with histologically confirmed
breast cancer from these families were available. In 129 of these
179 patients, a BRCA1 mutation was proven by direct DNA-
testing in blood cells or tumour material or because of their posi-
tion in the pedigree. Six breast cancer patients who were identified
as not carrying the familial BRCA1 mutation were excluded. Of
the remaining 173 breast cancer patients, nine patients were
excluded either because they were diagnosed with synchronous
bilateral breast cancer (n = 4; 2%) or because they underwent
bilateral mastectomy at the time of diagnosis of the first primary
(n = 5); finally 164 patients were evaluated.
The date of a second contralateral primary breast tumour, date
of bilateral mastectomy and date of death were selected as end-
points. Occurrence of a second contralateral breast cancer was
studied in relation to the age of onset of the first primary breast
cancer (Tables 1 and 2). Incidence rates and 95% confidence inter-
vals were calculated assuming a Poisson distribution. Finally the
cut-off age at first diagnosis of 50 years was chosen because
this age is frequently used to make the distinction between
premenopausal vs postmenopausal breast cancer (Early Breast
Cancer Trialists’ Collaborative Group, 1998). Kaplan–Meier prob-
abilities were computed with respect to the contralateral breast
cancer-free and overall survival and differences were tested by the
logrank test.
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Median age at diagnosis of the 164 patients with unilateral breast
cancer and follow-up was 41 years (range 22–80). The four
women (2%) with synchronous bilateral breast cancer that were
excluded from the analyses presented with breast cancer at the
ages of 33, 34, 34 and 51 years. Table 1 shows the number of
patients diagnosed with breast cancer < 40 years, at 41–50 years,
51–60 years, and > 60 years, with the 2-, 5- and 10-year contralat-
eral breast cancer probabilities for the different age-groups. The
annual incidence of contralateral breast cancer in relation to age of
diagnosis of the first primary is listed in Table 2 as well as the
number contralateral cancers that occurred and the number of
women years at risk. No contralateral cancers were observed in the
11 patients that were older than 60 years at time of diagnosis of the
first breast cancer.
Forty (24%) of the 164 patients were diagnosed with their first
breast cancer after the age of 50. Thirty-six (29%) of the remaining
124 patients diagnosed before the age of 50 years developed
metachronous contralateral breast cancer vs three (7.5%) of the 40
patients over the age of 50 on diagnosis (P = 0.005). Median
follow-up of all 164 patients was 47 months and the overall
survivall at 5 and 10 years was 66% and 50%, respectively.
Between the two age groups there was no significant difference in
overall survival (Plogrank = 0.98, Figure 1).
In the actuarial outcomes after 5 and 10 years follow-up,
metachronous contralateral breast cancer was found in 24% and
34%, respectively, of all BRCA1-associated breast cancer patients.
In the group of patients diagnosed with breast cancer before the
age of 50, contralateral breast cancer after 5 and 10 years follow-
up was seen in 30% and 40%, respectively, vs 4% and 12% respec-
tively in BRCA1-associated breast cancer patients older than 50
years at first diagnosis (Plogrank = 0.02, Figure 2).
DISCUSSION
In the general population, young age at onset of first breast cancer
has been shown to be a risk factor for the occurrence of contralat-
eral breast cancer. However the proportion of breast cancer due to
genetic susceptibility will also correlate with a younger age at
onset of the disease. With regard to the contribution of BRCA1
mutations to breast cancer in the general population it has previ-
ously been estimated that 5.3% of the women diagnosed before the
age of 40 carry this mutation, compared to only 1.1% of those aged
50–70 at diagnosis (Ford et al, 1995). Population-based studies in
early-onset breast cancer patients confirm these results (Newman
et al 1998; Peto et al, 1999). Therefore, young age at onset as a
risk-factor for contralateral breast cancer could at least partly be
due to the fact that early-onset breast cancer is more frequently the
result of genetic susceptibility, whereas a woman with breast
cancer resulting from genetic susceptibility could be at an
increased risk of developing contralateral breast cancer regardless
of the age at onset of her disease. In the present study we show that
with respect to BRCA1-associated breast cancer this risk is also
correlated with the age at onset of the first breast cancer.
We are not sure of the relevance of these results to the manage-
ment of contralateral breast cancer risk in BRCA2-associated
breast cancer patients, or patients with a strong family history for
the disease in general. Earlier we reported that the 5-year rate of
contralateral breast cancer in BRCA2 mutation carriers was 12%
(Verhoog et al, 1999). In the present study the rate in BRCA1
mutation-carriers is approximately twice that. Our present results
are well in line with studies showing that the breast cancer risk in
BRCA1 carriers declines with age (Easton et al, 1995). Although
the penetrance at ages < 50 years is less for BRCA2 mutations, the
life-time penetrance for breast cancer due to BRCA2 mutations
may be equal to that of BRCA1 mutation carriers (Ford et al,
1998). This could indicate that, in BRCA2 mutation carriers, the
risk for developing contralateral breast cancer does not diminish
after the menopause.
Because it was not possible to test all the breast cancer patients
from families with an identified BRCA1 mutation for the presence
of such a specific mutation, it cannot be ruled out that a few of the
patients in our series are in fact sporadic cases. However, restric-
tion to proven BRCA1 carriers did not essentially alter the
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Table 1 Actuarial contralateral breast cancer risk for 164 BRCA1-
associated breast cancer patients in relation to the age at diagnosis of the
first primary breast cancer (BC)
Age at n (%) of
Follow-up
first BC patients 2-year 5-year 10-year
≤40 74 (45) 0.08 0.21 0.27
41–50 50 (30) 0.09 0.33 0.52
51–60 29 (18) 0.04 0.04 0.15
> 60 11 (7) 0.00 0.00 0.00
Table 2 Annual incidence of contralateral breast cancer (CBC) in BRCA1-
associated breast cancer patients in relation to the age at diagnosis of the
first primary breast cancer (BC)
Age at Woman-years Incidence per year
first BC at risk CBC (n) of CBC (95% CI)
≤ 40 419 19 4.5% (2.9–7.1)
41–50 268 17 6.3% (3.7–10.6)
51–60 184 3 1.6% (0.4–4.8)
>60 56 0 0 (0–6.6)
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Figure 1 Overall survivall for BRCA1-associated breast cancer patients
(< 50 years at first diagnosis, n = 124, continuous line; > 50 years at first
diagnosis, n = 40, dashed line).386 LC Verhoog et al
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observed trend although numbers were to small to reach statistical
significance.
Since the 1980s breast cancer in postmenopausal women with
axillary lymph node involvement is generally treated with adju-
vant hormonal therapy, i.e. tamoxifen for 2–5 years while 4–6
courses of adjuvant chemotherapy are preferentially used in
premenopausal patients. Long-term adjuvant treatment with
tamoxifen resulted in a 45% reduction of the risk of contralateral
breast cancer (Early Breast Cancer Trialists’ Collaborative Group,
1998). This might partly explain the lower rate of contralateral
breast cancer in women diagnosed after the age of, 50. In our
series of 40 postmenopausal patients, information on the use of
antiestrogens was available for 36 patients; only six received adju-
vant tamoxifen therapy. Exclusion of these six women did not
essentially alter the observed trend, which makes this therapy an
unlikely explanation of the observed difference in the rate of
contralateral breast cancer between the two age-groups in our
study.
In conclusion, these results suggest that apart from the stage of
the primary tumour, and time that has elapsed since the onset of
disease, age at diagnosis of the first breast cancer in BRCA1 gene-
mutation carriers should be taken into account in the decision-
making process with respect to contralateral prophylactic
mastectomy.
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Figure 2 Proportion of BRCA1-associated breast cancer patients without
contralateral breast cancer.